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Abstract
Background: Adipocyte fatty acid-binding protein (A-FABP) has been reported to play critical roles in the
development of atherosclerosis. We investigated whether an increased in plasma A-FABP level can be
independently associated with the presence of coronary artery disease (CAD).
Methods: Two hundred eleven consecutive male patients (mean age: 66 years, range: 33-87 years) were enrolled
from inpatients who underwent coronary angiography. Age-matched male subjects (n = 211) having no evidence
of CAD served as controls. Plasma A-FABP levels were measured by enzyme-linked immunosorbent assays.
Results: Plasma A-FABP levels in CAD patients were significantly higher than in control subjects (median [IQR], 20.6
[15.7-27.8] ng/mL vs. 15.1 [11.7-19.9] ng/mL, p < 0.01). Multivariate logistic regression analysis revealed that an
increased plasma A-FABP level was independently associated with the presence of CAD in all subjects (adjusted
odds ratio: 1.76, 95% confidence interval: 1.14 to 2.70, p = 0.01). Furthermore, sub-analysis based on age showed
that this association remained significant in subjects aged < 65 years (adjusted odds ratio: 3.06, 95% confidence
interval: 1.34 to 6.98, p < 0.01), but not in subjects aged ≥65 years.
Conclusions: Increased plasma A-FABP in non-elderly men had a significant association with the presence of CAD,
independent of established CAD risk factors.
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Introduction
Adipocyte fatty acid-binding protein (A-FABP), also
known as aP2 or FABP4, is a small intracellular lipid-
binding protein [1]. There are nine types of FABPs, show-
ing tissue-specific expression patterns, and A-FABP is
abundantly expressed in adipocytes and macrophages [2].
Similar to other FABPs, recent studies showed that
A-FABP plays an essential regulatory role in energy meta-
bolism and inflammation [1]. The pathophysiological role
of this molecule has been investigated in murine experi-
mental models. A-FABP-deficient mice were protected
from the development of insulin resistance in diet-induced
obesity[3], type 2 diabetes [4], and atherosclerosis in
models of hypercholesterolemia [5]. A-FABP had an effect
on atherosclerosis due to not only the dysregulation of
systemic metabolism related with adipose tissue, as a
result of the activation of macrophages, as it was reported
that the expression of A-FABP in macrophages is induced
by oxidized low-density lipoprotein (LDL) [6], but also
Toll-like receptor activators [7]. It was also reported that
an inhibitor of A-FABP markedly reduced atherosclerotic
lesions in an ApoE-/- mouse model [5].
Clinically, the involvement of A-FABP in atherosclero-
sis is supported by a genetic study in human subjects.
A carrier of T-87 C polymorphism had lower serum tri-
glyceride levels, demonstrating a reduced cardiovascular
risk [8]. Moreover, although A-FABP was originally a
cytoplasmic protein, A-FABP levels could be detected in
human serum [9]. Higher serum A-FABP has been
reported to be useful for the prediction and diagnosis of
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mellitus. Previous studies also showed that the serum
A-FABP level predicts the development of metabolic
syndrome [10] and was associated with carotid intima-
media thickness [11], the number of stenotic coronary
arteries [12], and coronary plaque volume determined
by intravascular ultrasound (IVUS) [13]. These findings
demonstrated the role of A-FABP as a potential media-
tor of atherosclerotic diseases.
Therefore, understanding the clinical significance of
circulating levels of A-FABP may be useful for preventing
the development of cardiovascular diseases. In this study,
we investigated in a large population whether a higher
plasma A-FABP level is significantly associated with the
presence of CAD after adjustment for established cardio-
vascular risk factors. We also studied the relationship
between A-FABP and CAD according to age.
Methods
Study group
This study included 211 consecutive patients (mean age:
66 years, range: 33-87 years) with coronary artery dis-
ease (CAD) recruited to undergo coronary angiography,
from April 2008 to March 2009, at Kagawa Prefectural
Central Hospital, Japan. Patients with CAD had 75% or
greater organic stenosis of at least one major coronary
artery, confirmed by coronary angiogram, had suffered a
myocardial infarction, or had previously undergone
percutaneous transluminal coronary angioplasty or cor-
onary artery bypass graft surgery. Patients with hemo-
dialysis, acute coronary syndrome, recent myocardial
infarction within 4 weeks, and malignancies were
excluded. Control male subjects (n = 211), matched
with CAD patients for age (mean age: 66 years, range:
35-85 years), were selected from patients who visited
our affiliated hospitals. Controls were characterized by
no history of angina or other heart diseases, a normal
resting ECG, and normal exercise ECG stress testing.
This study protocol complied with the Declaration of
Helsinki and was approved by the Ethics Committees of
the institute. Informed consent was obtained from all
patients before the study entry.
Clinical and Biochemical assessment
Blood samples were taken after overnight fasting. The
plasma was separated and stored at-80°C, and plasma
levels of A-FABP (Biovendor Laboratory Medicine,
Modrice, Czech Republic) and high sensitivity C-reactive
protein (hsCRP; R&D Systems, Minneapolis, MN) were
measured by enzyme-linked immunosorbent assay, as
previously described[13]. The performance characteris-
tics of these assays were < 7 and < 8% CV intra-assay,
and < 5 and < 7% CV inter-assay for A-FABP and
hsCRP, respectively.
Risk factors were defined as follows. Diabetes was
confirmed according to the criteria of the American
Diabetes Association [14], or from a history of diabetes
mellitus treatment. Dyslipidemia was defined as one or
more of the following criteria: (1) serum triglyceride
≥150 mg/dL, (2) HDL-cholesterol < 40 mg/dL, (3) LDL-
cholesterol ≥130 mg/dL, (4) already on lipid-lowering
drugs. Hypertension was defined as a resting blood pres-
sure of ≥140/90 mmHg or on regular antihypertensive
medications. Smoking was defined as current smokers.
eGFR was calculated by the Modification of Diet in
Renal Disease (MDRD) equation [15] with coefficients
modified for Japanese patients [16]: eGFR (ml/min/1.73
m
2 ) = 194 × (serum creatinine)
-1.094 × (age)
- 0.287 Ann
Intern Med 130 . Renal dysfunction was defined as
eGFR < 60 ml/min/1.73 m
2 .
Coronary angiography
Coronary angiography was performed according to
standard methods. After intracoronary injection of
isosorbide dinitrate, angiograms were obtained in two or
more views. The coronary angiogram was scored by two
independent investigators and according to three techni-
ques [17]: (1) Vessel score: The number of vessels with
significant stenosis defined as 50% or greater luminal
diameter narrowing. (2) Stenosis score: A modified Gen-
sini score, which has been previously reported. Briefly,
the most severe stenosis in each of eight segments was
graded according to severity, from 1 to 4. The scores in
each of the eight segments were added to give a total
score out of 32. (3) Extent score: According to the pro-
portional length of each vessel segment in the coronary
artery tree, segments were graded with different maxi-
mum numbers of points, as previously reported. The
scores of each vessel were added to give a total score
out of 100. Stenosis score and extent score may be
regarded to reflect the coronary plaque burden.
Statistical analysis
Continuous variables are presented as the mean ± SD or
median (interquartile range) and differences between two
groups were evaluated with an unpaired t -test or the
Mann-Whitney U test, where appropriate. Categorical
variables are presented by frequency counts, and inter-
group comparisons were analyzed by the chi-square test.
Data that were not normally distributed, determined
using the Kolmogorov-Smirrnov test, were logarithmi-
cally transformed before linear regression analysis. Differ-
ences in plasma A-FABP across the scores of coronary
angiography were compared by one-way analysis of var-
iance (ANOVA), followed by the Bonferroni post-hoc
test. Associations between CAD and all other parameters
were first analyzed by simple logistic regression analysis
a n dt h e nb ym u l t i v a r i a t ea n a l y s i s .T h em u l t i v a r i a t e
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dence intervals (CIs). Statistical significance was defined
as p < 0.05. Statistical analysis was performed using SPSS
11.0 for Windows (SPSS Inc., Chicago, IL).
Results
Patient characteristics
Plasma A-FABP levels in CAD patients were signifi-
cantly higher than in control subjects (median [IQR],
20.6 [15.7-27.8] vs. 15.1 [11.7-19.9], p < 0.001, Figure 1).
The clinical characteristics of male CAD patients and
control subjects are shown in Table 1. In the fourth
quartile (plasma A-FABP level ≥24.5 ng/mL), the num-
ber of CAD patients was 2-fold that of control subjects,
while in the first quartile, the number of CAD patients
were less than that of control subjects. CAD patients
had a significantly higher body mass index, fasting blood
glucose, LDL cholesterol, and hsCRP, and lower level of
HDL cholesterol and eGFR. The presence of hyperten-
sion, diabetes mellitus, dyslipidemia, and smoking habit
was significantly higher in CAD patients than in control
subjects.
A m o n gd i a b e t i cp a t i e n t s( n=1 5 5 ) ,t h ep r e s e n c eo f
CAD was higher in those with over the medium level of
plasma A-FABP than in those with the lower plasma
A-FABP (84% vs. 64%, p < 0.01). Among patients with
dyslipidemia (n = 245), the presence of CAD was higher
in those with over the medium level of plasma A-FABP
than those with lower plasma A-FABP (78% vs. 54%,
p < 0.01).
In all subjects, plasma A-FABP was correlated with
the body mass index (r = 0.47, p < 0.001), but not with
age (r = 0.01, p = 0.86), LDL-cholesterol level (r = 0.07,
p = 0.15), or HbA1c (r = 0.09, p = 0.15). Plasma
A-FABP in subjects with a history of smoking was signifi-
cantly higher than that in subjects without a history of
smoking (19.6 [15.1-27.2] vs. 17.2 [12.7-24.1], p = 0.03). In
each CAD group or control group, medications did not
affect the plasma A-FABP level (data not shown).
Plasma A-FABP and the severity of CAD
The association of plasma A-FABP and three angio-
graphic scores, the vessel score, extent score, and modi-
fied Gensini score, were analyzed in CAD patients. The
level of plasma A-FABP did not differ among patients
with one diseased vessel (20.1 [15.3-28.1]), two diseased
vessels (20.9 [15.8-27.4], and three diseased vessels (21.6
[16.7-20.9]). Meanwhile, the extent score and the modi-
fied Gensini score were correlated significantly with a
stepwise increase in plasma A-FABP (Figure 2).
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Figure 1 Box-and whisker plot showing plasma levels of A-
FABP in CAD patients and control subjects. In these plots, lines
within boxes represent median values; upper and lower lines in the
boxes represent the 25
th and 75
th percentiles, respectively, and
upper and lower lines outside boxes represent the 90
th and 10
th
percentiles, respectively.
Table 1 Clinical characteristics of control subjects
and CAD patients
Control Subjects
(n = 211)
CAD Patients
(n = 211)
Age, years 66 ± 10 66 ± 11
Body mass index, kg/m
2 23.4 ± 2.9 24.9 ± 3.5*
Smoking, n(%) 29(13) 51(24)*
A-FABP (ng/mL) 15.1 (11.7-19.9) 20.6 (15.7-27.8)*
Diabetes Mellitus, n(%) 39(18) 116(55)*
FBS (mg/dL) 98(92-109) 104(95-126)*
Hypertension, n(%) 65(31) 156(72)*
Dyslipidemia, n(%) 83(39) 162(77)*
LDL-C (mg/dL) 105(85-122) 124(97-134)*
HDL-C (mg/dL) 58 ± 12 43 ± 11*
Triglycerides (mg/dL) 126 (105-151) 129(90-170)
eGFR(ml/min/1.73 m
2) 75.6 ± 17.6 66.9 ± 18.1*
hsCRP(mg/L) 0.67(0.29-1.68) 1.62(0.60-3.02)*
Medications
ACEI/ARBs 28(13) 82(39)*
CCBs 44(21) 91(43)*
Diuretics 18(9) 30(14)
b-blockers 23(11) 54(26)*
Statins 55(26) 126(60)*
Thiazolidinediones 15(7) 23(11)
Data are the mean ± SD, median (interquartile range), or frequency counts, as
appropriate. A-FABP, adipocyte fatty acid-binding protein; FBS, fasting blood
glucose; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density
lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; hsCRP, high
sensitivity C-reactive protein; ACEI, angiotensin-converting enzyme inhibitor;
ARB, angiotensin II receptor blocker; CCBs, calcium channel blockers.
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To assess the relation of each factor with CAD patients,
simple logistic regression analysis was performed
(Table 2). The body mass index, smoking, plasma A-FABP
level, diabetes mellitus, fasting blood glucose, hyperten-
sion, dyslipidemia, LDL cholesterol, HDL cholesterol,
renal dysfunction, eGFR, and hsCRP were significantly
associated with the presence of CAD. The uses of angio-
tensin-converting enzyme inhibitors/angiotensin II recep-
tor blockers (ACEIs/ARBs), calcium channel blockers
(CCBs), b-blockers, and statins were also significantly
associated with the presence of CAD statistically; however,
the following parameters were dependent on each other;
fasting blood glucose and diabetes mellitus, lipid profile
and dyslipidemia, and eGFR and renal dysfunction. There-
fore, diabetes mellitus, dyslipidemia and renal dysfunction
were selected as variates for multiple logistic regression
analysis, along with body mass index, smoking, hsCRP,
plasma A-FABP, and the use of ACEI/ARBs, CCBs,
b-blockers, and statins. Multiple logistic regression analy-
sis, including all the above factors revealed that the
increase in plasma A-FABP was independently associated
with the presence of CAD (p = 0.01) along with traditional
CAD risk factors.
Furthermore, to evaluate the impact of plasma A-FABP
on CAD presence according to age, we analyzed patients
aged < 65 years and ≥65 years separately (Table 3). For
analysis of subjects aged < 65, age-matched control
subjects (n = 92) against CAD subjects aged < 65 years
(n = 102) were re-selected from the control group. The
mean ages of the control group and CAD group were
comparable (57 ± 6 years and 57 ± 6 years, respectively).
Simple logistic regression analysis demonstrated that
plasma A-FABP, smoking, body mass index, diabetes
mellitus, hypertension, dyslipidemia, renal dysfunction,
hsCRP, and the use of ACEI/ARBs, CCBs, and statins
were significant factors associated with the presence of
CAD, Multiple logistic regression analysis including all
significant factors in subjects aged < 65 years revealed
that the increase in plasma A-FABP was independently
associated with the presence of CAD (p = 0.001) along
with smoking and diabetes mellitus. Next, for analysis of
subjects aged >65, control subjects (n = 93) age-matched
against CAD subjects aged >65 years (n = 109) were
re-selected from the control group. The mean ages of the
control and CAD groups were 75 ± 5 years and 75 ± 6
years, respectively. Simple logistic regression analysis
demonstrated that plasma A-FABP, diabetes mellitus,
hypertension, dyslipidemia, renal dysfunction, hsCRP,
and the uses of ACEI/ARBs, CCBs, b-blockers and statins
were significant factors associated with the presence of
CAD; however, multiple logistic regression analysis
including all significant variates revealed that plasma
A-FABP was not an independent factor associated
with CAD.
Discussion
In the present study, we demonstrated that higher level
of plasma A-FABP in male subjects was independently
associated with the presence of CAD after adjustment for
established cardiovascular risk factors, such as smoking,
diabetes mellitus, dyslipidemia, hypertension, and smok-
ing. Our multivariate logistic analysis demonstrated that
the adjusted odds ratio of plasma A-FABP (per doubling)
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Figure 2 Association of plasma A-FABP with extent score (A) and modified Gensini score (B) . Closed boxes: mean; vertical bars: 95%CI. *
p < 0.05
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Page 4 of 7for the presence of CAD was 1.78 (95%CI: 1.14-2.70,
p = 0.01). Furthermore, sub-analysis based on age showed
that this association remained significant in subjects aged
< 65 years, but not in subjects aged ≥65 years.
A-FABP and CAD
Several lines of evidence have suggested the role of
A-FABP in atherogenesis, and it is possible that the
high plasma A-FABP levels in patients with CAD in
this study were the cause of progressive coronary
atherosclerosis. Studies on the molecular function of
A-FABP in macrophages have shown that A-FABP
deficiency reduced foam cell formation in response to
oxidized LDL and increased the cholesterol efflux
pathway[18]. A-FABP-deficient mice also showed a
significant decrease of vascular atherosclerosis in the
absence of differences in serum lipids or insulin sensi-
tivity in hyperlipidemia model mice, and this effect
was attributed to the action of A-FABP in macro-
phages[5]. Thus, A-FABP in macrophages and adipo-
cytes has pathological effects on vessels. In humans,
cohort studies suggested that A-FABP plays an impor-
tant role in insulin resistance and metabolic syndrome
[9]. Our study shows that diabetic patients over the
medium level of plasma A-FABP had a significantly
greater presence of CAD than diabetic patients with
l o w e rp l a s m aA - F A B P .T h e s er e s u l t ss u g g e s tt h a t
plasma A-FABP may have a differential impact on
CAD from diabetes mellitus. A previous cross-
sectional study, however, showed that serum A-FABP
was correlated closely with risk factors characterized
by abdominal obesity, including insulin resistance,
hyperglycemia, increased serum triglyceride, LDL-cho-
lesterol, and decreased HDL-cholesterol[9]. Our find-
ings also found that plasma A-FABP had a weak
correlation with hsCRP and eGFR (data not shown). In
addition, previous studies showed that medications
affect the circulating A-FABP level. Serum A-FABP
was reported to be reduced with statin therapy [19],
but increased with the treatment of thiazolidinedione
[20]. Despite several confounding factors, multiple
logistic regression analysis demonstrated that plasma
A-FABP was independently associated with the pre-
sence of CAD after adjustment for well-known CAD
risk factors, hsCRP, and renal dysfunction. Thus,
increased plasma A-FABP can be considered a candi-
date risk factor for CAD, although a large-scale pro-
spective study in the general population is needed.
Table 2 Logistic regression analysis in whole subjects
Simple Multiple
Factors Crude OR(95%CI) p Adjusted OR (95%CI) p
Body mass index (per kg/m
2) 1.163 (1.090-1.240) < 0.001 1.024 (0.940-1.117) 0.584
Smoking (yes) 2.000 (1.201-3.308) 0.006 2.408 (1.140-2.703) 0.012
A-FABP (per doubling) 3.008 (2.158-4.194) < 0.001 1.755 (1.140-2.703) 0.010
Diabetes Mellitus (yes) 5.385 (3.465-9.369) < 0.001 4.896 (2.799-8.562) 0.001
FBS (per doubling) 11.978 (4.819-29.772) < 0.001
Hypertension (yes) 6.371 (4.169-9.737) < 0.001 3.830 (1.755-8.360) < 0.001
Dyslipidemia (yes) 5.099 (3.342-7.779) < 0.001 1.857 (0.903-3.817) 0.092
LDL-C (per mg/dL) 0.992 (0.986-9.999) 0.024
HDL-C (per mg/dL) 0.905 (0.887-0.823) < 0.001
Triglycerides (per doubling) 1.003 (1.000-1.007) 0.676
Rrenal dysfunction (yes) 2.465 (1.559-3.899) < 0.001 1.787 (0.946-3.375) 0.074
eGFR (per ml/min/1.73 m
2) 0.972 (0.961-0.984) < 0.001
hsCRP (per doubling) 1.379 (1.215-1.564) < 0.001 1.436 (1.216-1.697) < 0.001
Multiple logistic regression analysis included variates in bold in simple regression analysis and the use of ACEI/ARB, CCBs, b-blockers, and statins. R2 = 0.364 (n = 422)
Table 3 Significant factors associated with CAD in
younger and elder subjects
Subjects aged < 65 years Adjusted OR (95%CI) p
A-FABP (per doubling) 3.063 (1.343-6.987) 0.001
Smoking (yes) 2.877 (1.001-8.231) 0.04
Diabetes Mellitus (yes) 6.937 (2.759-17.438) < 0.001
Subjects aged>65 years Adjusted OR (95%CI) p
Diabetes Mellitus (yes) 3.633 (1.602-8.238) 0.002
Hypertension (yes) 4.633 (1.602-8.238) 0.011
hsCRP (per doubling) 1.519 (1.210-1.908) < 0.001
The model in subjects aged < 65 years included plasma A-FABP, smoking,
body mass index, diabetes mellitus, hypertension, dyslipidemia, renal
dysfunction, hsCRP, and the use of ACEI/ARBs, CCBs, and statins. The model in
subjects aged>65 years included plasma A-FABP, diabetes mellitus,
hypertension, dyslipidemia, renal dysfunction, and hsCRP, the use of ACEI/
ARBs, CCBs, b-blockers and statins. Only statistical significant factors are
presented in Table 3.
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A-FABP is expressed in adipocytes and macrophages,
and an increase in plasma A-FABP may reflect an
increased expression in those cells. Plasma A-FABP con-
centration has been reported to be correlated with caro-
tid atherosclerotic parameters, such as intima-media
thickness[11]and plaque volume of the coronary artery
determined with IVUS[13]. In line with previous studies,
we demonstrated that plasma A-FABP in CAD patients
increased with the severity of angiographic coronary
stenosis[12]. Besides the severity of coronary stenosis,
previous studies showed thatp l a q u ev u l n e r a b i l i t yi s
more important for future cardiac events[21]. Extent of
atherosclerosis is another marker of an increased risk of
coronary events. There is a significant association
between coronary artery calcium scores, that reflects the
actual presence and severity of atherosclerosis, and car-
diovascular events [22]. In our study, A-FABP level was
closely associated with modified Gensini score and
extent score, that reflect coronary plaque burden. Thus,
A-FABP might have potential to be a predictor of cardi-
ovascular outcomes.
Several studies showed that genetic involvement in
adipokine regulation was associated with atherosclerosis
[23]. Regarding A-FABP, the T-87 C allele in the pro-
moter region of the A-FABP gene has been shown to be
associated with lower triglyceride levels, a reduced risk
for coronary artery disease and type 2 diabetes [8].
Recent genetic studies identified several candidate genes
associated with type 2 diabetes, including KCNQ1 [24],
while A-FABP also contributed to the development of
diabetes mellitus. In fact, a previous study showed that
circulating A-FABP could predict the development of
type 2 diabetes [10]. A basic experiment showed that
interplay between FABPs and pancreatic islets plays an
important role insulin secretion [25]. Thus, even though
the direct interaction between A-FABP polymorphism
and atherosclerosis has not been fully elucidated, the
influence of A-FABP on lipid and glucose metabolism
[26]may be one of the important mechanisms of
atherosclerosis.
In this study, multivariate analysis using traditional
CAD risk factors revealed that the association between
elevated plasma A-FABP and the presence of CAD
remain significant in patients aged < 65 years, but not
in subjects aged ≥65 years. This finding is similar to pre-
dictive power of cardiovascular risk factors in relation to
aging. Several studies documented that impact of risk
factors on mortality decreases with age, partly because
of selective survival and the influence of comorbidity on
risk factor levels [27-29]. For instance, increased systolic
blood pressure or cholesterol in younger subjects may
affect cardiovascular mortality events with low-grade
elevation or short-term exposure, more than in subjects
of advanced age. On the other hand, the effect of each
factor for risk control would be reduced in subjects of
advanced age. As the progression of coronary artery dis-
ease is the manifestation of a cluster of several risk fac-
tors, the impact of A-FABP on the development of
atherosclerosis would be reduced in subjects of
advanced age; thus, the impact of increased plasma
A-FABP can be regarded as a coronary risk factor espe-
cially in patients aged < 65 years.
Gender difference in circulating A-FABP
This study focused on men, because male gender is an
important risk factor of CAD and gender differences in
serum A-FABP have been reported [13]. Previously, we
have shown that serum A-FAPB in female patients with
CAD was significantly higher than in male patients with
CAD, whereas serum A-FABP in men was lower than in
women. This contradictory difference in serum A-FABP
in women might confuse the analysis of the interaction;
therefore, we analyzed only men in this study. This sex
difference may be partly the result of the relatively
higher fat percentage in women than in men, because
adipose tissue is the major contributor of circulating
A-FABP. Another explanation is the regulation of
A-FABP expression by sex hormones. A study showed
that the secretion of adiponectin, which is another
major adipokine, was suppressed by testosterone [30]. A
similar mechanism of the secretion of A-FABP might be
possible. Further studies will be needed to elucidate the
clinical implication of increased plasma A-FABP in
women in respect of CAD.
Conclusion
An increase in circulating A-FABP in men was demon-
strated to be independently associated with the presence
of CAD after adjustment for established cardiovascular
risk factors. Further, the plasma A-FABP had more
impact on CAD in non-elderly men than in elderly men.
Our findings indicated that A-FBAP might be a clini-
cally significant mediator linking obesity and coronary
atherosclerosis, and the measurement of circulating
A-FABP may be useful to evaluate the risk of CAD.
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